Oasis Management Co Ltd. Increases Stake in Grifols, S.A. (NASDAQ:GRFS)

Oasis Management Co Ltd. grew its stake in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 19.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,157,607 shares of the biotechnology company's stock after buying an additional 191,137 shares during the period. Grifols accounts for about 1.9% of Oasis Management Co Ltd.'s investment portfolio, making the stock its 11th largest position. Oasis Management Co Ltd. owned about 0.17% of Grifols worth $8,613,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Helikon Investments Ltd purchased a new position in Grifols during the fourth quarter valued at $580,000. Norges Bank purchased a new position in shares of Grifols during the fourth quarter valued at about $14,434,000. GAMMA Investing LLC grew its position in shares of Grifols by 44.5% during the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 1,527 shares in the last quarter. Barclays PLC increased its holdings in shares of Grifols by 381.2% in the third quarter. Barclays PLC now owns 592,552 shares of the biotechnology company's stock worth $5,261,000 after purchasing an additional 469,401 shares during the last quarter. Finally, LPL Financial LLC lifted its position in shares of Grifols by 25.0% in the fourth quarter. LPL Financial LLC now owns 75,398 shares of the biotechnology company's stock worth $561,000 after buying an additional 15,067 shares in the last quarter.

Grifols Trading Up 8.9%

Shares of GRFS opened at $7.73 on Tuesday. The company's fifty day moving average is $7.32 and its 200 day moving average is $7.64. Grifols, S.A. has a fifty-two week low of $5.79 and a fifty-two week high of $9.96. The stock has a market capitalization of $5.31 billion, a PE ratio of 6.61 and a beta of 0.44. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley initiated coverage on Grifols in a report on Wednesday, February 12th. They set an "overweight" rating for the company.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.